CMPX: Compass Therapeutics, Inc.
Performance
CMPX -80.22%
Watchlist
Select an item
Summary
CMPX at a glance
CMPX returned -80.22% over the past year and -25.41% a year over five years. Its worst drop in that year was -89.77%, smaller than 0% of stocks on Redstone, and its Sharpe ratio of -1.03 beats 4% of stocks on Redstone. It pays no dividends.
Current Drawdown
-87.49%
Rolling Volatility
79.45%
Actions
Metrics
Risk Indicators
Alpha-115.67%
Beta1.60x
Sharpe-1.03
Sortino-1.18
Omega0.80
Calmar-0.89
Martin-1.82
Profile
About CMPX
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $151M
- Listed
- Nov 2020
- Employees
- 39
- Headquarters
- Boston, MA
- Website
- compasstherapeutics.com
Comparisons